Core Service Pillar 5

Evidence Synthesis & Scientific Publications

Publication-grade Systematic Literature Reviews (SLR), quantitative Meta-Analyses, and high-impact peer-reviewed manuscripts conforming to PRISMA, Cochrane, and ICMJE guidelines.

From Complex Clinical Data to Peer-Reviewed Impact

Publishing in top-tier medical journals (Q1/Q2 impact factor) and supporting Health Technology Assessments (HTA) requires more than raw data; it demands immaculate research methodology, reproducible literature synthesis, and strict adherence to international publication ethics (ICMJE, GPP4, and COPE).

Kensai Health provides comprehensive evidence synthesis and medical publication services backed by decades of biopharma, CRO, and academic research rigor. We support biopharma sponsors, academic consortia, and clinical investigators from initial protocol conceptualization through peer-review acceptance.

We synthesize vast clinical datasets into authoritative systematic reviews, quantitative meta-analyses, and compelling trial manuscripts that withstand intense scientific scrutiny.

šŸ“

Peer-Reviewed Journal Manuscripts

Complete manuscript authoring and editing for primary clinical trial results, retrospective cohort studies, and secondary post-hoc analyses. We ensure adherence to target journal Instructions for Authors, ICMJE criteria, and EQUATOR guidelines (CONSORT, STROBE).

  • • Primary clinical trial papers
  • • Post-hoc & subgroup analysis papers
  • • Expert reviews & clinical consensus reports
šŸ”Ž

Systematic Literature Reviews (SLR)

Exhaustive, reproducible systematic reviews conforming to PRISMA 2020 guidelines and Cochrane Handbook methodologies. We build sensitive database search algorithms across PubMed, Embase, Scopus, Web of Science, and Cochrane Central.

  • • PROSPERO protocol pre-registration
  • • Rayyan / Covidence dual screening support
  • • Risk-of-bias assessment (Cochrane RoB 2 / ROBINS-I)
šŸ“Š

Quantitative Meta-Analysis

Pooling trial data across published studies to evaluate overall treatment effect sizes, odds ratios, hazard ratios, and relative risks. We construct publication-ready forest plots and funnel plots to assess publication bias.

  • • Fixed-effects and random-effects models
  • • Heterogeneity assessment (Cochran Q & I² statistic)
  • • Egger's test and Begg's funnel plots
Peer-Reviewed Track Record

Selected Publications and Writing Contributions

Demonstrated scholarly authority across digital therapeutics, clinical trials, and medical communication standards.

Publications

  • • Garg KR, Kabra G, Pandey KK, Mishra V, Kaushal AK. Accelerating digital health innovation adoption: prioritizing critical enablers of digital therapeutics for diabetes care in India. International Journal of Innovation Science. 2026 Oct 30:1-34.
  • • Garg KR, Mishra, V, Pandey, KK. Harnessing technology for diabetes care: a review of digital therapeutics. BMJ Innovations. 2026;12(2):110-118. https://doi.org/10.1136/bmjinnov-2024-001340
  • • Garg KR, Pandey, KK, Kabra, G. Sustainable digital health: integrating AI and circular economy principles. In A. Samadhiya, A. Kumar, S. O. Idowu, & P. Dutta (Eds.), Handbook on Artificial Intelligence and the Circular Economy (Chap. 18). 2026 Mar 17. (1st ed., pp. 279-297). Edward Elgar Publishing. https://doi.org/10.4337/9781035343386.00028
  • • Garg KR, Mishra V, Pandey KK, Kabra G, Kaushal A. Deciphering the evolution of digital therapeutics: A bibliometric analysis of clinical trials. Proceedings of Singapore Healthcare. 2025;34:20101058251335692. doi:10.1177/20101058251335692
  • • Garg K. Sales Training and Beyond: Developing Educational Content Across the Pharma/Biotech Landscape: Open Session Report. AMWA. 2022;37(1). doi:10.55752/amwa.2022.117
  • • Garg K. Teaching the Next Generation of Regulatory Medical Writers: Open Session Report. AMWA. 2022;37(1). doi:10.55752/amwa.2022.118
  • • Garg K. How Apprenticeships Can Help New Medical Writers Get Started. Blog. Originally published on 22 July 2019; Refreshed and republished by AMWA in October 2023
  • • Garg S, Srivastava S, Singh K, Sharma A, Garg K. Ulcer healing potential of ethanolic extract of Caralluma attenuata on experimental diabetic rats. Anc Sci Life 2016;35:222-226. doi:10.4103/0257-7941.188182
  • Contribution in Publications

  • • Wyles, D.L., Matsuda, K., Iwaki, Y. et al. Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study. BMC Pulm Med 26, 218 (2026). https://doi.org/10.1186/s12890-026-04261-8
  • • Wen L. 2022 Walter C. Alvarez Award Address: Emerging Issues Following COVID-19: Public Health Communication. AMWA. 2023;38(1). doi:10.55752/amwa.2023.235
  • • Chawla P, Shunmugavelu M, Jaggi S, et al. Expert Opinion by Clinicians on the Use of Insulin Therapy in People with Hepatic Impairment. J Assoc Physicians India 2023;71(2):78-85.
  • • Oskarsson B, Maragakis N, Bedlack RS, Goyal N, Meyer JA, Genge A, et al. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegenerative disease management. 2021;11(6):431-43.
  • • Fofani N, Markandeywar N, Desai S. Prevalence and incidence of asthma among underprivileged children in polluted urban areas of India: a childhood asthma intervention and referrals study. Int J Community Med Public Health 2018;5:4166-9.
  • • Shah CP, Shah BP, Dani SI, Channa BB, Lakshmanan SS, Krishnamani NC, et al. Efficacy and safety of the intensive dose of rosuvastatin 40 mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Indian Heart J 2016; 68(6):766-771.
  • • Rauthan A, Dattatreya PS, Singhal M, Prabu R, Naik S, Kukreja A. Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer. Asian J Oncol 2015;1:84-91